Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 5/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.48 |
| ▸ | MIF | P14174 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BACH1 | O14867 | 1/20 | 0.42 |
| ▸ | MAFK | O60675 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607282 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL5070755 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL1607124 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL1607149 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL14933784 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL14933787 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL25332541 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL1606718 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL2485837 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| Sulforaphane SCHEMBL20855320 | 0.98 | NAAA (0.50) | NAAATRPA1MIFGSK3BKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629349-B2 | Recognition ability improving agent | KINJIRUSHI CO., LTD. (JP) | 2026-05-19 | — | — | US | claimed |
| EP-3820290-B1 | FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS | UNIV LAUSANNE (CH) | 2025-07-02 | — | — | EP | claimed |
| EP-3666277-B1 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER | NUTRAMAX LAB INC (US) | 2025-05-07 | — | — | EP | claimed |
| US-12178800-B2 | Sulforaphane-melatonin-like compound | PERPETUUM VENTURES NV (BE) | 2024-12-31 | — | — | US | claimed |
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2024-12-26 | — | — | US | claimed |
| CN-119110723-A | Blood flow increasing agent for dorsolateral prefrontal cortex, activating agent for dorsolateral prefrontal cortex, food for increasing blood flow for dorsolateral prefrontal cortex, and food for activating dorsolateral prefrontal cortex | 金印株式会社 | 2024-12-10 | — | — | CN | claimed |
| US-20240316134-A1 | BLOOD FLOW INCREASING AGENT FOR DORSOLATERAL PREFRONTAL CORTEX, DORSOLATERAL PREFRONTAL CORTEX ACTIVATOR, FOOD FOR INCREASING BLOOD FLOW IN DORSOLATERAL PREFRONTAL CORTEX, AND FOOD FOR ACTIVATING DORSOLATERAL PREFRONTAL CORTEX | KINJIRUSHI CO., LTD. (JP) | 2024-09-26 | — | — | US | claimed |
| CN-118340268-A | Raw material composition of food preparation, preparation method and application thereof | 宁波宁瑞生物科技有限公司 | 2024-07-16 | — | — | CN | claimed |
| EP-4346861-A1 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MORINGA PLANT COMPONENTS | NUTRAMAX LABORATORIES, INC. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20240041733-A1 | DENTAL CARE COMPOSITION AND METHOD OF PROMOTING CALCIFICATION IN LIVING BODY TISSUE | KINJIRUSHI CO., LTD. (JP) | 2024-02-08 | — | — | US | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| US-6737441-B2 | PREVENTING OR TREATING PERSISTENT CHRONIC GASTRITIS, ULCERS AND/OR STOMACH CANCER | Fahey, Jed W. | 2004-05-18 | — | — | US | claimed |
| CN-1469711-A | Treatment of helicobacter with isothiocyanates | W | 2004-01-21 | — | — | CN | claimed |
| WO-2003068202-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP ASSETS B.V. (NL) | 2003-08-21 | — | — | WO | claimed |
| EP-1313377-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | Fahey, Jed W. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20030064131-A1 | Method for preparing isothiocyanate(s) from cruciferous plant material | JAPANESE R AND D ASSOC. FOR NEW FUNCTIONAL FOODS (JP) | 2003-04-03 | — | — | US | claimed |
| US-20020151505-A1 | Treatment of helicobacter with isothiocyanates | FAHEY, JED W. | 2002-10-17 | — | — | US | claimed |
| US-6465512-B2 | BRINGING THE LEUKEMIC CELLS INTO CONTACT WITH A LEUKEMIC CELL GROWTH INHIBITOR WHICH IS A METHYLSULFINYLALKYL ISOTHIOCYANATE REPRESENTED BY THE GENERAL FORMULA CH3-SO-(CH2)N- N HORIZONTAL-LINE C HORIZONTAL-LINE S | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2002-10-15 | — | — | US | claimed |
| WO-2002015722-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2002-02-28 | — | — | WO | claimed |
| US-20020022655-A1 | Leukemic cell growth inhibiting method | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2002-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | NAAA 3132/4885TRPA1 230/4885MIF 2014/4885 |
| US-12629349-B2 | Recognition ability improving agent | TAS2R8, TST, FABP7 | NAAA 271/4885TRPA1 790/4885MIF 3298/4885 |
| US-12178800-B2 | Sulforaphane-melatonin-like compound | MTNR1B, MTNR1A, HNMT | NAAA 3508/4885TRPA1 1935/4885MIF 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.